[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "Montefiore Medical Center-Weiler Hospital",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Histologically confirmed adenocarcinoma of the breast that is Her2 negative (by DAKO Herceptest, fluorescence in situ hybridization [FISH], or other approved assay)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Metastatic breast cancer not amenable to potentially curative surgery; patients must have disease that is measurable and/or non-measurable as defined by RECIST 1.1 criteria (assessed by computed tomography [CT] scan chest/abdomen/pelvis with contrast or fludeoxyglucose [FDG] positron emission tomography [PET]-CT scan obtained within 4 weeks of registration)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Prior therapy\r\n* Arm A: Rebastinib plus paclitaxel: up to two prior non-taxane chemotherapy regimens for metastatic or incurable locally advanced disease permitted (no prior paclitaxel or eribulin); patients with estrogen receptor (ER)-positive disease are required to have relapse or progression on at least one line of endocrine therapy\r\n* Arm B: Rebastinib plus eribulin: up to three prior chemotherapy regimens for metastatic or incurable locally advanced disease permitted (no prior eribulin, but prior paclitaxel allowed): patients with ER-positive disease are required to have relapse or progression on at least one line of endocrine therapy"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Leukocytes >= 3,000/uL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Absolute neutrophil count >= 1,500/uL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Platelets >= 100,00/uL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Hemoglobin > 9 g/dL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Total bilirubin within normal institutional limits"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Creatinine within normal institutional limits"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "Left ventricular ejection fraction at or above institutional lower limits of normal (by echocardiogram within 12 weeks of registration)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "Electrocardiogram (EKG) corrected QT interval (QTc) < 450 msec (females)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Serum calcium & phosphorus within normal institutional limits"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Glucose within normal institutional limits"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 16,
                    "description": "Negative urine or serum beta-human chorionic gonadotropin (BHCG) for women of childbearing potential only (within 7 days of registration)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 17,
                    "description": "No prior known history of retinal neovascularization, macular edema or macular degeneration; patients without such a history are required to have a baseline ophthalmologic exam as part of screening, and must not have evidence of retinal neovascularization, macular edema or macular degeneration on the screening exam in order to be eligible"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 18,
                    "description": "Patients must be disease-free of prior invasive malignancies for >= 2 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix; patient with the following prior concurrent diagnoses are eligible: lobular carcinoma in situ, contralateral ductal carcinoma in situ, or contralateral invasive ductal and/or lobular carcinoma"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 19,
                    "description": "Women of child-bearing potential must not be pregnant or breast feeding; they must also agree to use adequate contraception (hormonal or barrier method of birth control) and not be breast feeding prior to study entry, for the duration of study participation, and for up to 30 days after completion of all protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study or up to 30 days after completion of protocol therapy, she should inform her treating physician immediately"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 20,
                    "description": "Ability to understand and the willingness to sign a written informed consent document"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 21,
                    "description": "At least 30 days from major surgery before study enrollment, with full recovery"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 22,
                    "description": "Concomitant therapy with bisphosphonates, RANKL inhibitors or growth-colony-stimulating factors (G-CSF) is allowed as per physician decision"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 23,
                    "description": "Patients for the expansion cohort must have a CTC (TelomeScan) drawn in the screening phase if other eligibility criteria are met, and must be CTC-positive in order to be eligible for enrollment in the expansion cohort"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "History of allergic reactions attributed to compounds of similar chemical or biological composition to rebastinib or other agents used in the study (e.g., Cremophor)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 25,
                    "description": "History of cardiac disease, including: (a) myocardial infarction within 6 months of the start of study, (b) history of QTc prolongation or QTc >= 450 msec on screening EKG, history of additional risk factors for torsade de pointes (e.g., heart failure, hyperkalemia), and family history of long QT syndrome; (c) use of concomitant drugs that prolong QT/QTc interval; (d) New York Heart Association class III or IV heart disease, (e), active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically signification cardiac arrhythmia requiring therapy"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 26,
                    "description": "Intercurrent illness that would substantially increase the risk of treatment associated complications (e.g., active infection, uncontrolled diabetes mellitus or hypertension) and/or psychiatric illness/social situations that would interfere with the patient's ability to comply with the treatment regimen"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 27,
                    "description": "Patients with human immunodeficiency virus (HIV) infection are excluded from the study"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 28,
                    "description": "Patients with untreated brain metastasis are excluded; patients with a prior history of brain metastasis are eligible if they have received prior brain radiation, have improved or stable intracranial disease for at least 3 months after completion of last course of radiation, and are not taking corticosteroids for treatment of brain metastasis; patients with a prior history of brain metastases who meet other eligibility criteria"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 29,
                    "description": "Treatment with other chemotherapy regimen within the past 2 weeks"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 30,
                    "description": "Treatment with trastuzumab, bevacizumab or other targeted therapies within the past 4 weeks"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "FEMALE",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": null,
        "detail_description": "PRIMARY OBJECTIVES:\r\nI. To determine the recommended phase II dose (Arm A1-dose escalation cohort) and overall safety profile (Arm A2-expansion cohort) of rebastinib tosylate (rebastinib) (50 mg orally [PO] twice daily [BID] or 100 mg PO BID) given concurrently with weekly paclitaxel (80 mg/m^2 weekly x 12) over 3 consecutive weeks (1 cycle) in patients with breast cancer. (Arm A)\r\nII. To determine the recommended phase II dose (Arm B1-dose escalation cohort) and overall safety profile (Arm B2-expansion cohort) of rebastinib (50 mg PO BID or 100 mg PO BID) given concurrently with weekly eribulin mesylate (eribulin) (1.4 mg/m^2 days 1 and 8 every 21 days) over 3 consecutive weeks (1 cycle) in patients with breast cancer. (Arm B)\r\n\r\nSECONDARY OBJECTIVES:\r\nI. To determine the objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1), progression-free survival, and overall survival of patients treated with rebastinib plus paclitaxel, and rebastinib plus eribulin (at all rebastinib dose levels). (Arm A1-2 and Arm B1-2)\r\nII. To determine correlation between rebastinib plasma concentration and angiopoietin (ANG1 and/or ANG2) levels. (Arm A1-2 plus Arm B1-2)\r\nIII. To perform an exploratory analysis of the effects of rebastinib plus antitubulin therapy on circulating tumor cell (CTCs) during cycle 1. (Arm A2 plus Arm B2)\r\nIV. To perform an exploratory analysis of the effects of rebastinib plus antitubulin therapy on TIE-2 expressing monocytes (TEM) during cycle 1. (Arm A2 plus Arm B2)\r\nV. To perform an exploratory analysis of the effects of rebastinib plus antitubulin therapy on tumor microenvironment of metastasis (TMEM) score and TMEM function in a cohort of up to 6 patients with metastatic cancer who have their primary tumor in place and are agreeable to up to 2 research biopsies of the primary tumor before and during (i.e., after 3 weeks of) rebastinib therapy. (Arm A2 or Arm B2)\r\n\r\nOUTLINE: This is a dose-escalation study of rebastinib tosylate. Patients are assigned to 1 of 2 arms.\r\n\r\nARM A2: Patients receive rebastinib tosylate PO BID beginning on days 1-21 of courses 1 or 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel intravenously (IV) over 1 hour on day 1. Treatment repeats weekly for up to 12 weeks in the absence of disease progression or unacceptable toxicity.\r\n\r\nARM B2: Patients receive rebastinib tosylate PO BID beginning on days 1-21 of courses 1 or 2. Patients also receive eribulin mesylate IV over 3-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\r\n\r\nAfter completion of study treatment, patients are followed up for 30 days and for up to 3 years.",
        "official_title": "Phase Ib Study of Rebastinib plus Antitubulin Therapy with Paclitaxel or Eribulin in Patients with Metastatic Breast Cancer",
        "_phase_sort_order": 4,
        "collaborators": [
            {
                "name": "National Cancer Institute",
                "functional_role": "FUNDING_SOURCE"
            }
        ],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Up to 3 years",
                "name": "Adverse event rates",
                "description": "Will be computed with a 95% CI.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Angiopoietin levels",
                "description": "Will examine the Pearson, as well as the Spearman correlation between the drug concentration levels measured using Cmax and angiopoietin levels.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline up to 3 years",
                "name": "Change in CTC levels assessed by Telome Scan",
                "description": "Will be evaluated using the two-sample t-test. The magnitude of the change (mean difference or ratio) and 95% confidence interval (CI) will also be evaluated by Wilcoxon Signed Rank test.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline up to 3 years",
                "name": "Changes in TMEM score and function",
                "description": "Will be compared using a Wilcoxon Signed Rank test. The magnitude of change either using the mean difference or ratio will be reported along with its 95% CI.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
                "description": "Adverse effects will be summarized using frequency tables. Results will be summarized using descriptive statistics and associations will be evaluated using Fisher exact test.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Overall survival",
                "description": "Will be assessed by Kaplan Meier method.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years",
                "name": "Progression-free survival",
                "description": "Will be assessed by Kaplan Meier method.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Rebastinib tosylate drug levels",
                "description": "Will examine the Pearson, as well as the Spearman correlation between the drug concentration levels measured using maximum concentration (Cmax) and angiopoietin levels.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Response rates assessed by RECIST 1.1",
                "description": "Will be computed with a 95% CI.",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT02824575",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25871",
                "name": "Phosphotransferase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C25870",
                    "C16612",
                    "C21281"
                ],
                "parents": [
                    "C25870"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "ERBB2 Negative",
                    "HER-2 Negative",
                    "HER2 Negative"
                ],
                "nci_thesaurus_concept_id": "C68749",
                "name": "HER2/Neu Negative",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C165233",
                    "C16612",
                    "C17756",
                    "C3367",
                    "C21295",
                    "C35681",
                    "C20719",
                    "C25870",
                    "C16152",
                    "C36292",
                    "C25872",
                    "C94299",
                    "C77140",
                    "C20103",
                    "C21281",
                    "C25871"
                ],
                "parents": [
                    "C16152",
                    "C165233",
                    "C17756"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Genes"
                ],
                "nci_thesaurus_concept_id": "C16612",
                "name": "Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "branch"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C94299",
                "name": "Receptor Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C77140"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ERBB2",
                    "Erb-b2 Receptor Tyrosine Kinase 2 Gene",
                    "HER2",
                    "HER2/Neu",
                    "NEU"
                ],
                "nci_thesaurus_concept_id": "C17756",
                "name": "ERBB2 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612",
                    "C21295",
                    "C20719",
                    "C25870",
                    "C25872",
                    "C20103",
                    "C21281",
                    "C25871"
                ],
                "parents": [
                    "C20719"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25872",
                "name": "Kinase Family Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C25870",
                    "C16612",
                    "C21281",
                    "C25871"
                ],
                "parents": [
                    "C25871"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C20103",
                "name": "Receptor Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612",
                    "C21295"
                ],
                "parents": [
                    "C21295"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C21295",
                "name": "Ligand Binding Protein Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Negative"
                ],
                "nci_thesaurus_concept_id": "C35681",
                "name": "Negative Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C21281",
                "name": "Enzyme Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25870",
                "name": "Transferase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612",
                    "C21281"
                ],
                "parents": [
                    "C21281"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Absent",
                    "LOST",
                    "Loss of Expression",
                    "Negative",
                    "Not Expressed"
                ],
                "nci_thesaurus_concept_id": "C165233",
                "name": "Expression Negative",
                "semantic_types": [
                    "Cell or Molecular Dysfunction"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C35681",
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C35681"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ERBB2 Status",
                    "Her2/Neu Value"
                ],
                "nci_thesaurus_concept_id": "C16152",
                "name": "HER2/Neu Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C16612",
                    "C17756",
                    "C21295",
                    "C20719",
                    "C25870",
                    "C36292",
                    "C25872",
                    "C94299",
                    "C77140",
                    "C20103",
                    "C21281",
                    "C25871"
                ],
                "parents": [
                    "C17756",
                    "C94299"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C20719",
                "name": "Receptor Tyrosine Kinase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612",
                    "C21295",
                    "C25870",
                    "C25872",
                    "C20103",
                    "C21281",
                    "C25871"
                ],
                "parents": [
                    "C20103",
                    "C25872"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": "SAFETY",
        "current_trial_status_date": "2021-12-27",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Stage IV Breast Cancer AJCC v7",
                    "Stage IV Breast Cancer AJCC v6",
                    "Stage IV Breast Carcinoma",
                    "Breast Carcinoma Stage IV",
                    "Breast Cancer Stage IV",
                    "Stage IV Breast Cancer AJCC v6 and v7"
                ],
                "nci_thesaurus_concept_id": "C3995",
                "name": "Stage IV Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C90513",
                    "C91230"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Adenocarcinoma of the Breast",
                    "Mammary adenocarcinoma",
                    "Adenocarcinoma of Breast"
                ],
                "nci_thesaurus_concept_id": "C5214",
                "name": "Breast Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4872",
                    "C2852"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasms, NOS",
                    "Neoplasia",
                    "Tumor, NOS",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplastic Disease",
                    "tumor",
                    "Neoplasm, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Epithelioma",
                    "Epithelioma, malignant",
                    "Epithelial Neoplasms, NOS"
                ],
                "nci_thesaurus_concept_id": "C3709",
                "name": "Epithelial Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4741"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Breast Carcinoma by AJCC v6 Stage"
                ],
                "nci_thesaurus_concept_id": "C90513",
                "name": "Breast Cancer by AJCC v6 Stage",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4872"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Breast Carcinoma by AJCC v7 Stage"
                ],
                "nci_thesaurus_concept_id": "C91230",
                "name": "Breast Cancer by AJCC v7 Stage",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4872"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Disease",
                    "Diseases and Disorders",
                    "disease type",
                    "Disease or Disorder",
                    "Diagnosis",
                    "disease_term",
                    "condition",
                    "disease_type",
                    "Diseases",
                    "Disease or Disorder, Non-Neoplastic",
                    "Disorders",
                    "Disorder"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm of Breast",
                    "Neoplasm of the Breast",
                    "Tumor of Breast",
                    "Tumor of the Breast",
                    "Breast Tumor"
                ],
                "nci_thesaurus_concept_id": "C2910",
                "name": "Breast Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3263",
                    "C26709"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Tumor of the Breast",
                    "Malignant Neoplasm of the Breast",
                    "Malignant Neoplasm of Breast",
                    "Malignant Breast Tumor",
                    "Malignant Tumor of Breast"
                ],
                "nci_thesaurus_concept_id": "C9335",
                "name": "Malignant Breast Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2910",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Malignant Growth",
                    "Tumor, malignant, NOS",
                    "Malignant Tumor",
                    "Malignancy",
                    "CA",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C3263",
                "name": "Neoplasm by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "CARCINOMA, MALIGNANT",
                    "Malignant Epithelial Tumor",
                    "Malignant Epithelial Neoplasm",
                    "Epithelial Carcinoma",
                    "Malignant Epithelioma",
                    "Carcinoma",
                    "Carcinoma, NOS",
                    "Epithelial tumor, malignant",
                    "Epithelioma Malignant"
                ],
                "nci_thesaurus_concept_id": "C2916",
                "name": "Other Carcinoma",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C3709",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Mammary Carcinoma",
                    "Carcinoma of Breast",
                    "Carcinoma of the Breast",
                    "Breast cancer, NOS",
                    "Cancer of Breast",
                    "Breast Carcinoma",
                    "Cancer of the Breast"
                ],
                "nci_thesaurus_concept_id": "C4872",
                "name": "Breast Cancer",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2916",
                    "C9335"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Breast Disease",
                    "Breast Diseases"
                ],
                "nci_thesaurus_concept_id": "C26709",
                "name": "Breast Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Disease by Site"
                ],
                "nci_thesaurus_concept_id": "C27551",
                "name": "Disorder by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor Morphology",
                    "Tumor_Morphology"
                ],
                "nci_thesaurus_concept_id": "C4741",
                "name": "Neoplasm by Morphology",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Glandular Cell Epithelium Neoplasm",
                    "Glandular Cell Epithelial Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C7132",
                "name": "Glandular Cell Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3709"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Adenocarcinoma, NOS",
                    "ADENOCARCINOMA, MALIGNANT"
                ],
                "nci_thesaurus_concept_id": "C2852",
                "name": "Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2916",
                    "C7132"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "2016-6488",
        "active_sites_count": 0,
        "lead_org_cancer_center": "Albert Einstein Cancer Center",
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Taxanes"
                        ],
                        "nci_thesaurus_concept_id": "C1490",
                        "name": "Taxane Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C860"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C43431",
                        "name": "Activity",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C82693",
                        "name": "Rebastinib Tosylate",
                        "description": "An orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the  receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against  T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C129825",
                            "C1967"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Lab Test",
                            "Lab Tests",
                            "Test",
                            "Tests",
                            "Laboratory Test"
                        ],
                        "nci_thesaurus_concept_id": "C25294",
                        "name": "Laboratory Procedure",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Agent",
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Drug"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C64263",
                        "name": "Laboratory Biomarker Analysis",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C63333",
                            "C74957"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Hydrocarbons"
                        ],
                        "nci_thesaurus_concept_id": "C552",
                        "name": "Hydrocarbon",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Protein Antagonist",
                            "Anti-cancer Protein Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C63333",
                        "name": "Biomarker Analysis",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C718",
                        "name": "Organic Chemical",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1913"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129824",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Lipids"
                        ],
                        "nci_thesaurus_concept_id": "C616",
                        "name": "Lipid",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Agents",
                            "Antiproliferative Agents",
                            "Antiproliferative Drugs",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Antineoplastic Drugs",
                            "Anti-Tumor Drugs",
                            "Antineoplastics",
                            "Cancer Drug",
                            "Tumor-Specific Treatment Agents",
                            "Anti-Cancer Agents"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1404",
                        "name": "Protein Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1913",
                        "name": "Drug or Chemical by Structure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antimitotic Drugs",
                            "Mitosis Inhibitor Drugs",
                            "Mitosis Inhibitors",
                            "Antimitotics",
                            "Mitosis Inhibitor Agents",
                            "Mitotic Inhibitor Drugs",
                            "Microtubular Function Inhibitors",
                            "Mitotic Inhibitors",
                            "Mitotic Inhibitor Agents"
                        ],
                        "nci_thesaurus_concept_id": "C273",
                        "name": "Antimitotic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Bristaxol",
                            "Taxol Konzentrat",
                            "Praxel",
                            "Asotax",
                            "Anzatax"
                        ],
                        "nci_thesaurus_concept_id": "C1411",
                        "name": "Paclitaxel",
                        "description": "A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1490",
                            "C67437"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Terpenes"
                        ],
                        "nci_thesaurus_concept_id": "C860",
                        "name": "Terpene Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C552",
                            "C616"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C16203",
                        "name": "Clinical or Research Activity",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C43431"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Tubulin Binding Agents"
                        ],
                        "nci_thesaurus_concept_id": "C25974",
                        "name": "Tubulin Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C273"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Taxane-Site Binding Agent"
                        ],
                        "nci_thesaurus_concept_id": "C67437",
                        "name": "Taxane-Pocket Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25974"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Protein Tyrosine Kinase Inhibitors",
                            "TK Inhibitors",
                            "PTK Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1967",
                        "name": "Tyrosine Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1404"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Intervention",
                            "Procedure",
                            "Intervention Strategies"
                        ],
                        "nci_thesaurus_concept_id": "C25218",
                        "name": "Intervention or Procedure",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C16203"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Agent",
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Pharmacologic Agent",
                            "Drug",
                            "Pharmacological Substance",
                            "Pharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C74957",
                        "name": "Mixed Category Laboratory Procedure",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C25294"
                        ]
                    }
                ],
                "name": "Arm A2 (rebastinib tosylate, paclitaxel)",
                "description": "Patients receive rebastinib tosylate PO BID beginning on days 1-21 of courses 1 or 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 1 hour on day 1. Treatment repeats weekly for up to 12 weeks in the absence of disease progression or unacceptable toxicity.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C43431",
                        "name": "Activity",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C82693",
                        "name": "Rebastinib Tosylate",
                        "description": "An orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the  receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against  T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C129825",
                            "C1967"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Lab Test",
                            "Lab Tests",
                            "Test",
                            "Tests",
                            "Laboratory Test"
                        ],
                        "nci_thesaurus_concept_id": "C25294",
                        "name": "Laboratory Procedure",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Agent",
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Drug"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C64263",
                        "name": "Laboratory Biomarker Analysis",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C63333",
                            "C74957"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Protein Antagonist",
                            "Anti-cancer Protein Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C63333",
                        "name": "Biomarker Analysis",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Vinca-Domain Binding Agents",
                            "Vinca-Site Binding Agents",
                            "Vinca-Site Binding Agent"
                        ],
                        "nci_thesaurus_concept_id": "C67422",
                        "name": "Vinca-Domain Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25974"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129824",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Agents",
                            "Antiproliferative Agents",
                            "Antiproliferative Drugs",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Antineoplastic Drugs",
                            "Anti-Tumor Drugs",
                            "Antineoplastics",
                            "Cancer Drug",
                            "Tumor-Specific Treatment Agents",
                            "Anti-Cancer Agents"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1404",
                        "name": "Protein Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antimitotic Drugs",
                            "Mitosis Inhibitor Drugs",
                            "Mitosis Inhibitors",
                            "Antimitotics",
                            "Mitosis Inhibitor Agents",
                            "Mitotic Inhibitor Drugs",
                            "Microtubular Function Inhibitors",
                            "Mitotic Inhibitors",
                            "Mitotic Inhibitor Agents"
                        ],
                        "nci_thesaurus_concept_id": "C273",
                        "name": "Antimitotic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C16203",
                        "name": "Clinical or Research Activity",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C43431"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Tubulin Binding Agents"
                        ],
                        "nci_thesaurus_concept_id": "C25974",
                        "name": "Tubulin Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C273"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Protein Tyrosine Kinase Inhibitors",
                            "TK Inhibitors",
                            "PTK Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1967",
                        "name": "Tyrosine Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1404"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Halaven"
                        ],
                        "nci_thesaurus_concept_id": "C26644",
                        "name": "Eribulin Mesylate",
                        "description": "The mesylate salt of  a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C67422"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Intervention",
                            "Procedure",
                            "Intervention Strategies"
                        ],
                        "nci_thesaurus_concept_id": "C25218",
                        "name": "Intervention or Procedure",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C16203"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Agent",
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Pharmacologic Agent",
                            "Drug",
                            "Pharmacological Substance",
                            "Pharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C74957",
                        "name": "Mixed Category Laboratory Procedure",
                        "description": null,
                        "type": "Other",
                        "category": "other",
                        "parents": [
                            "C25294"
                        ]
                    }
                ],
                "name": "Arm B2 (rebastinib tosylate, eribulin mesylate)",
                "description": "Patients receive rebastinib tosylate PO BID beginning on days 1-21 of courses 1 or 2. Patients also receive eribulin mesylate IV over 3-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2016-01662",
        "why_study_stopped": "Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.",
        "brief_summary": "This phase Ib trial studies the best dose and side effects of rebastinib tosylate when given together with paclitaxel or eribulin mesylate in treating patients with HER2 negative breast cancer that has spread to other parts of the body. Rebastinib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rebastinib tosylate with paclitaxel or eribulin may work better in treating patients with breast cancer.",
        "brief_title": "Rebastinib Tosylate and Paclitaxel or Eribuilin Mesylate in Treating Patients with HER2 Negative Metastatic Breast Cancer",
        "status_history": [
            {
                "status_date": "2021-12-27T00:00:00.000004",
                "status": "ADMINISTRATIVELY_COMPLETE"
            },
            {
                "status_date": "2016-07-15T00:00:00.000003",
                "status": "ACTIVE"
            },
            {
                "status_date": "2016-07-14T00:00:00.000002",
                "status": "ACTIVE"
            },
            {
                "status_date": "2016-07-14T00:00:00.000001",
                "status": "APPROVED"
            },
            {
                "status_date": "2016-05-25T00:00:00",
                "status": "IN_REVIEW"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 60,
        "_current_trial_status_sort_order": 8,
        "start_date": "2016-07-14",
        "record_verification_date": "2022-02-11",
        "ctep_id": null,
        "current_trial_status": "Administratively Complete",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": "OPEN",
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Randomized Controlled Trial"
        },
        "acronym": null,
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Breast"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": "Jesus Del Santo Anampa Mesias",
        "study_source": "Institutional",
        "completion_date": null,
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]